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Recombinant vaccinia virusInterleukin-15 (IL-15) is a potent growth factor for activated T and natural killer (NK) cells, stimulator of
memory T cells and plays an important role in viral immunity. To investigate mechanisms underlying the
antiviral activity of IL-15, a recombinant vaccinia virus (rVV) encoding murine IL-15 (VV-IL-15) was
constructed. Following infection of mice with VV-IL-15, virus titres in the ovaries were signiﬁcantly reduced
compared to mice infected with control VV. Growth of VV-IL-15 was also reduced in nude athymic mice,
indicating the antiviral activity of IL-15 does not require T cells. Additionally, VV-IL-15 augmented the
cytolytic activity of natural NK cells in the spleen and enhanced interferon (IFN) mRNA expression and
transcription factors associated with IFN induction. Using knockout mice and antibody depletion studies, we
showed for the ﬁrst time that the control of VV-IL-15 replication in mice is dependent on NK cells and IFNs
and, in their absence, the protective role of IL-15 is abolished.
© 2009 Elsevier Inc. All rights reserved.Introduction
The early stages of viral infection are controlled by the induction
of non-speciﬁc immune cells including natural killer (NK) cells,
dendritic cells and macrophages, and by the production of cytokines
including interferons (IFNs). Cytokines and chemokines are largely
produced by T cells and macrophages and they control multiple
arms of the antiviral immune response (Ramshaw et al., 1997;
Mahalingam et al., 2001c).
Interleukin-15 (IL-15) is a cytokine with antiviral activity, sharing
a number of key functions with IL-2 (Grabstein et al., 1994). Both IL-2
and IL-15 have a similar tertiary structure and belong to the four
alpha-helix bundle family of cytokines. Although IL-15 shares
common receptor subunits with IL-2 for signal transduction (the IL-
2Rα and IL-2R subunits), each cytokine utilises a different receptor
subunit for high-afﬁnity binding (Tagaya et al., 1996). The common
biological functions of IL-2 and IL-15 include stimulation of NK cells,
induction of T and B cell proliferation, and the stimulation of cytokine
secretion (Armitage and Alderson, 1995; Carson et al., 1994;
Waldmann and Tagaya, 1999). Although IL-15 shares many of the
biological effects of IL-2, signiﬁcant differences exist at the molecular
and cellular level between these two cytokines (Fehniger andecular and Chemical Sciences,
anberra, ACT 2601, Australia.
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ll rights reserved.Caligiuri, 2001; Waldmann et al., 2001). Exogenous administration
of IL-15 has been reported to regulate NK cell survival and stimulate
IFN production by NK cells (Carson et al., 1994; Puzanov et al., 1996).
Studies in knockout mice have demonstrated that IL-15 is required for
the development and survival of NK cells and both memory and
activated CD8+ T cells (Kennedy et al., 2000; Lodolce et al., 1998).
The presence of a virus-inducible region in the IL-15 promoter
suggests IL-15 is a component of host antiviral defense mechanisms
(Azimi et al., 2000). This has been conﬁrmed for infection with a
number of viruses including herpes simplex virus-1 (HSV-1), HSV-2
and vaccinia virus (VV) (Ahmad et al., 2000; Perera et al., 2001;
Tsunobuchi et al., 2000). IL-15 deﬁcient mice are unable to clear VV
infection (Kennedy et al., 2000), although these mice lack NK cells,
making interpretation of results difﬁcult. Landmark studies by Perera
et al. (2001) using a rVV encoding human IL-15 showed a direct
antiviral effect of IL-15. The rVV encoding IL-15 was cleared more
rapidly from mice than the corresponding control virus (Perera et al.,
2001). The mechanisms of protection in mice infected with rVV
expressing IL-15 were not established, although protection was
associated with increased NK cell numbers and IFN-γ production.
In this study, we sought to identify speciﬁc mechanisms of IL-15-
driven antiviral activity by investigating mechanisms of clearance of
rVV encoding IL-15 in mice. For these studies we developed rVV
encoding murine IL-15 (mIL-15). This differs from previous studies
which used human IL-15, and may be an important enhancement
since there is only 73% and 54% amino acid homology between the
human and mouse IL-15 gene (Anderson et al., 1995a) and receptor
Fig. 1. IL-15 mRNA and protein expression in vivo. (A) Time course of expression of
IL-15, IL-2, IFN-γ and the housekeeping gene HPRT mRNA in C57BL/6 mice following
infection with VV-WR. Total RNA was prepared from the spleens of groups of four
uninfected mice and infected mice at days 1, 3 and 6 post infection (p.i). (B and C)
Time course of IL-15 and IFN-γ protein production in C57BL/6 mice following
infection with VV-WR. Spleens from groups of three uninfected mice and infected
mice at days 1, 3 and 6 p.i. and were homogenized in PBS. Cytokine concentrations
in the supernatants were determined by ELISA.
Fig. 2. Protein expression by VV-IL-15. (A) Confocal images of ﬁxed, permeabilised cells
secondary antibody. Uninfected cells stained with both antibodies were used as a control. Tra
in response to two-fold dilutions of concentrated protein harvested from VV-infected cells.
signiﬁcantly higher than VV-X (pb0.0001).
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signaling potency between human andmouse IL-15 through the IL-15
receptor have been observed (Eisenman et al., 2002).
Virally encoded IL-15 enhanced viral clearance and prevented
mortality in athymic nude mice. The clearance of VV-IL-15 was found
to be mediated by increased levels of NK cell cytolytic activity and by
the induction of IFNs and associated transcription factors. We show,
for the ﬁrst time, that the protective role of IL-15 against VV infection
is dependent on the presence of IFNs.
Results
IL-15 is expressed early following VV infection and parallels IL-2
and IFN-γ expression
IL-15 mRNA expression was measured during VV infection to gain
insight into potential roles for IL-15 in antiviral immunity. Spleens
were removed from VV-infected C57BL/6 mice at days 1, 3, 6 10, 12
and 14 post infection (p.i). IL-15mRNAwas absent in uninfectedmice,
but rapidly upregulated following infection, with expression being
detectable by day 1, and peaking by day 3 (Fig. 1A). The expression of
IL-15 mRNA decreased rapidly after day 6, a timepoint that correlates
with virus clearance. IL-15 mRNA was not detected at days 10, 12 and
14 (data not shown). The kinetics of IL-15 mRNA expression was
similar to that observed for two known antiviral cytokines IL-2 and
IFN-γ (Fig. 1A).
In order to determine that the mRNA proﬁle reﬂected protein
expression, ELISAs for IL-15 and IFN-γ were performed on super-
natants of homogenized spleen tissues. Consistent with the mRNA
data, at various time points p.i., IL-15 protein correlated with IFN-γ
protein and peaked at day 6 (Figs. 1B, C). Since the kinetics of IL-15,
IFN-γ and IL-2 were similar, and both IFN-γ and IL-2 have previously
been shown to play important roles in the clearance of poxviruses, the
clear implication was that murine IL-15 may mediate similar
functions.
VV-IL-15 replication is attenuated in vivo
The role of IL-15 in mediating viral clearance in vivo was
investigated by constructing a rVV encoding mouse IL-15 (VV-IL-15).
Following infection of 143B cells with VV-IL-15, we were able to
conﬁrm that the infected cells produced IL-15 (Fig. 2A) and that this
IL-15 was fully bioactive (Fig. 2B). IL-15 could not be detected in
cultures infected with VV-X.infected with VV-IL-15 and stained with murine IL-15 antibody and FITC-conjugated
nsmission images of the same ﬁelds are shown on the right. (B) CTLL-2 cell proliferation
Cell proliferation is proportional to the absorbance at 490 nm. ⁎ indicates VV-IL-15 is
Table 1
Mortality of rVV-infected Swiss, nude mice.
Virus 104 pfu 105 pfu 106 pfu 107 pfu
VV-X 12.5% 25% 100% (10.8±0.2a) 100% (6.5±0.2a)
VV-IL-15 NM NM NM NM
VV-IL-2 NM NM NM NM
Groups of 7 mice were observed for 45 days.
NM: no mortality observed.
a The mean time to death (days)±SEM is given for groups with 100% mortality.
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determine the in vitro replication of the IL-15 encoding virus
compared to the control virus. The pattern of viral infectivity was
similar to the control virus over a period of 48 h before cell lysis
occurred (data not shown). This indicated that insertion and over-
expression of IL-15 by rVV neither affected the replication of the
vaccinia virus nor attenuated the virus in vitro.
Athymic Swiss outbred nude mice, which lack mature T cells, were
infected with rVV to investigate the effects of virus-expressed IL-15 in
vivo. Nude mice were highly susceptible to infection with VV-X,
showing 100% mortality at the higher doses (106–107 pfu), and 12.5%
mortality at 104 pfu, the lowest dose tested. Mice infected with the
higher doses of VV-X developed severe pox lesions during the ﬁrst
week of infection and demonstrated severe weight loss as well as
morbidity prior to death. In contrast, nude mice survived infection
with VV-IL-15 at all doses tested, with minimal weight loss and
morbidity (Table 1). For comparison, nude mice were infected with
VV-IL-2, a previously described rVV known to be highly attenuated
through its ability to stimulate strong NK- and T cell responses. Similar
to VV-IL-15, all mice infected with VV-IL-2 successfully cleared VV
infection. These results highlight the potent antiviral function of IL-15,
even in the absence of T cells.
To further assess the antiviral effects of IL-15, we investigated the
growth of rVV in ovaries of nude and wild-type mice. The ovary was
chosen for these studies since VV replicates to high titres in this organ.
Nude mice infected with VV-IL-15 exhibited markedly lower viral
titers compared to mice infected with VV-X at all time points tested
(pb0.01) (Fig. 3A). By day 1 post infection, there was already a 100-
fold reduction in virus titres inmice infectedwith VV-IL-15, indicating
that the antiviral activity of IL-15 is relatively rapid. The degree of
attenuation of VV-IL-15 in immunocompetent mice was similar to
that observed in nude mice (Fig. 3B). Although it is difﬁcult to make
direct comparisons between outbred nude mice and C56BL/6 mice,
the results indicate that a substantial component, if not all, of the
antiviral activity of the virus-encoded IL-15 is T cell independent.Fig. 3. Growth kinetics of rVV replication in ovaries of VV-infected Swiss nude mice (A) and
(Swiss nude) or 107 pfu (C57BL/6) rVV. Ovaries were collected from the mice on days 1, 3 an
The limit of detection of the assay is 2 log10 pfu/ml. At all timepoints themean viral titers of th
infected with VV-IL-15 and VV-IL-2 (one-way ANOVA, pb0.01).In these experiments, additional groups of mice were infected
with VV-IL-2, a virus that is highly attenuated due to heightened
activity of both NK cells and T cells. Using this comparison, we
conclude that IL-15 and IL-2 have comparable antiviral activity,
although IL-15 may be slightly less potent (Figs. 3A, B).
Histological analysis of stained ovarian sections revealed extensive
damage to the stromal tissue and follicles of ovaries in C57BL/6 mice
infected with VV-X (Fig. 4B). In mice infected with VV-IL-15 minimal
damage to the ovaries was observed (Fig. 4D), consistent with
reduced levels of virus replication in the ovary. Ovarian sections from
VV-IL-2-infected mice (Fig. 4C) displayed minimal histopathological
changes and were similar to ovarian sections from uninfected control
mice (Fig. 4A).
Splenic NK cytolytic activity is enhanced in VV-IL-15-infected mice
It is clear that early immunemechanismsplay a role in the clearance
of VV-IL-15, since virus load was dramatically reduced as early as day
one in mice infected with VV-IL-15 compared to VV-X. Several studies
have implicated IL-15 in NK cell activation (Biron and Brossay, 2001),
and we hypothesized that increased NK cell cytolytic activity
contributed to the enhanced clearance of VV-IL-15. SplenicNK cytolytic
activity was measured in groups of uninfected mice and mice infected
with VV-X and VV-IL-15. In some experiments VV-IL-2was included as
an additional control based on the ability of this virus to stimulate high
levels of NK activity (Karupiah et al., 1990). In both nude andwild-type
mice, NK cell cytolytic activity at day 1 p.i. was approximately 3-fold
higher in mice infected with VV-IL-15 than with VV-X (Figs. 5A, C;
pb0.05). The high NK cytolytic activity was not due to IL-15-induced
proliferation of NK cells as there was no increase in NK cell numbers in
mice infectedwith VV-IL-15 (data not shown). By day 3 therewas little
or no difference in NK cell activity betweenmice infectedwith VV-X or
VV-IL-15 (Figs. 5B, D). The heightened NK activity at day 1 following
infection with VV-IL-15 correlates well with the rapid clearance of this
virus (Fig. 3A), suggesting that enhanced NK cell activity may underlie
the antiviral activity of virus-encoded IL-15. TheNK cell activity inmice
infected with VV-IL-15 was generally less than that in mice infected
with VV-IL-2 (Figs. 5B, C, D), suggesting that the ability of IL-15 to
promote NK cell cytotoxicity may be less than that of IL-2.
IFNs, IRF-1 and NF-κb are upregulated in VV-IL-15-infected mice
IL-15 can induce the production of antiviral type I and type II IFNs
in NK cells, monocytes, macrophages and dendritic cells in vitro
(Carson et al., 1999; Jinushi et al., 2003; Liu et al., 2004). Therefore, the
role of IFNs in VV-IL-15-mediated protective responses wasC57BL/6 mice (B). Groups of 4 female mice were infected intravenously with 106 pfu
d 6 and the viral titers determined. Shown is the mean plus standard error of the mean.
e Swiss nude and C57BL/6mice infected with VV-Xwere signiﬁcantly higher thanmice
Fig. 4. Histological examination of ovaries from C57BL/6 mice infected with rVV.
Ovarian sections were harvested 6 days after mice were infected with 107 pfu of rVV
and stained with haematoxylin and eosin. Extensive damage to the stromal tissue (S)
and follicles (F) was evident in VV-X (B) infected ovaries. However, minimal
histopathological changes were observed in ovarian sections of VV-IL-2 (C) and VV-
IL-15 (D) infected mice, compared to an uninfected control (A). Images are at 100×
magniﬁcation.
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sacriﬁced on day 3 and the spleens collected for analysis of IFN
mRNA expression and protein. Virus-expressed IL-15 induced
considerably higher levels of IFN-β, IL-15, IFN-γ and IRF-1 mRNA
than in mice infected with VV-X (Fig. 6A). In addition, IL-15 and IFN-γ
protein levels were signiﬁcantly higher in VV-IL-15-infected mice
compared to control virus-infected animals (Figs. 6B, C; pb0.01). A
similar trend was seen in the ovaries with higher levels of IFN-γ
protein detected in VV-IL-5 infected mice compared to VV-X infectedFig. 5. Lysis of YAC-1 target cells by splenocytes from Swiss nude mice (A and B) and C57BL/
infection using spleen cells from VV-infected mice. Uninfected mice were used as controls.
than 5% and have been omitted for clarity. Asterisks indicate that NK cytolytic activity was sig
VV-X (one-way ANOVA, pb0.01).mice at 3 days after infection (data not shown). In a separate
experiment, the transcription factors IRF-1 and NF-κBwere examined.
These transcription factors bind to a common motif in the promoter
region of the genes for IFNs and several IFN-inducible genes. IRF-1 and
NF-κb levels were higher in the spleens of VV-IL-15 infectedmice than
in the spleens of mice infected with the control virus, VV-X (Figs. 6D,
E). Taken together, these results provide clear evidence of heightened
IFN activity in response to virus-encoded IL-15, and suggest a further
mechanism of IL-15-mediated antiviral activity.
In vivo NK cell depletion partially reverses the antiviral activity of
virus-encoded IL-15
In order to establish whether NK cells contributed to the control of
VV-IL-15 replication, mice were depleted of NK cells using a
monoclonal antibody (PK136) to NK1.1+ cells (Koo et al., 1986).
Administration of PK136 to mice infected with VV-X resulted in a
severe reduction in NK cytolytic activity (data not shown), thus
conﬁrming treatment efﬁcacy. In mice infected with VV-X, depletion
of NK cells had no effect on virus load in the ovaries (Fig. 7A), and a
moderate increase in the spleen (Fig. 7B). In contrast, virus load in the
ovary and spleen of VV-IL-15 infected mice was signiﬁcantly higher
following NK cell depletion (Fig. 7B). However, NK cell depletion in
VV-IL-15 infectedmice did not fully abrogate the attenuation of VV-IL-
15, since the titres in VV-IL-15 infectedmice did not return fully to the
levels in VV-X-infected mice. These results indicate that NK cells are
major contributors to the antiviral activity of virus-encoded IL-15, but
that additional factors may also participate.
We speculated that NK cells were also responsible for the
enhanced expression of IFNs in mice infected with VV-IL-15. In the
spleens of mice infected with VV-X or VV-IL-15, depletion of NK cells
markedly reduced expression of both IFN-γ and IFN-β (Figs. 7C, D).
This result suggested a potential mechanism for the antiviral activity
of NK cells in VV-IL-15 infected mice through the production of IFNs.
However, NK cell depletion did not fully block IFN mRNA expression,
especially for IFN-β, suggesting additional sources of IFN production.
The absence of IFNs abolish the protective role of IL-15
To test the role of IFNs in the antiviral activity of virus-encoded
IL-15, we employed a range of IFN- and IFN receptor knockout mice.
Following infection with VV-X, mice deﬁcient in IFN-γ or the IFN-γ
receptor showed 100% mortality. Similarly, mice deﬁcient in the IFN-6 mice (C and D). Natural killer cell cytolytic activity was measured on days 1 and 3 post
Data shown are the mean lysis values from 4 mice in each group. SEM values were less
niﬁcantly higher in VV-IL-15- or VV-IL-2-infected mice compared to mice infected with
Fig. 6. Analyses of cytokines and transcription factors in vivo. (A) Expression of IFN-γ, IFN-β, IRF-1, IFN-15 and the housekeeping gene HPRT mRNA transcripts in the spleens of
groups of 3 C57BL/6 mice three days post infection with VV-IL-15 and VV-X. (B and C) IL-15 and IFN-γ protein levels in the spleens of groups of 3 C57BL/6 uninfected mice andmice
infectedwith VV-IL-15 or VV-X (three days post infection). Cytokine concentrations in the supernatantswere determined by ELISA. Electrophoreticmobility shift assay showing IRF-1
and NF-κB activity in nuclear extracts prepared from the spleens of uninfected mice and mice infected (three days post infection) with recombinant vaccinia viruses.
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receptor, were fully susceptible to VV-X infection (Table 2). These
results conﬁrm the importance of both type I and type II IFN in
control of VV infection. In contrast, IFN-γ−/−, IFN-γ−/− R, and IFN-α/
β R−/− mice were fully resistant to infection with VV-IL-15. Only
mice lacking both IFN-γ receptor and IFN-α/β receptor were
susceptible to VV-IL-15 infection, showing 100% mortality (Table 2).
Virus load in the spleen and ovaries of IFN-deﬁcient mice 3 days
following rVV infection was also measured. VV-IL-15 grew to
signiﬁcantly higher titres in IFN-γ−/− and IFN-α/β−/− R mice than
in wild-type mice, although in neither deﬁcient mouse strain did the
virus load approach that of mice infected with VV-X (Table 3). In IFN-
α/β, γ R−/−mice the virus load in the ovaries and spleen was higher
than in mice deﬁcient in either IFN-γ or IFN-α/β signaling, and was
comparable to the virus load found in mice infected with VV-X
(Table 3). These results were conﬁrmed using neutralizing antibodies
to IFN-γ and IFN-α/β. Neutralization of either IFN resulted in
enhanced virus load in mice infected with VV-IL-15 (Table 4). Thevirus load in VV-IL-15-infected mice treated with neutralizing
antibodies to both IFN-γ and IFN-α/β was higher still, and similar to
that found in mice infected with VV-X. Taken together, the results
suggest that both IFN-γ and IFN-α/β contribute to the enhanced
clearance of VV-IL-15, and that in combination the IFNs largely
account for the antiviral activity of virus-encoded IL-15.
Discussion
IL-15 is involved in protection against several viral infections,
including human herpes viruses, HIV and inﬂuenza virus (Ahmad
et al., 2000; Chehimi et al., 1997; Fawaz et al., 1999). Most of these
studies were performed in vitro using human peripheral blood
mononuclear cells (PBMCs) infected with the relevant virus. A few
studies have shown that IL-15 has antiviral activity in vivo (Ashkar
and Rosenthal, 2003; Perera et al., 2001; Tsunobuchi et al., 2000). The
ability of IL-15 to promote NK cell activation is a major factor in the
antiviral activity of this cytokine (Fawaz et al., 1999). However, IL-15-
Fig. 7. Effects of natural killer (NK) cell depletion on viral titers and IFN levels. Groups of 4 female C57BL/6micewere depleted ofNK cells by intraperitoneal administration of the PK136
monoclonal antibody on days−1 and 1 and infected on day 0 with 107 pfu VV-X or VV-IL-15. Ovaries (A) and spleens (B) were harvested on day 3 and the viral titers determined. The
standard error of themean for each group is represented as error bars. ⁎ indicates a signiﬁcant difference between the groups. (C) Expression of IFN-γ, IFN-β and the housekeeping gene
HPRT in the spleens of groups of three NK depleted and non-depletedmice three days post infectionwith rVV. (D) IFN-γ protein levels in the spleens of groups of 3 C57BL/6 uninfected
mice, NK depleted and non-depleted mice three days post infection with rVV. Cytokine concentrations in the supernatants were determined by ELISA (⁎pb0.05).
Table 3
Replication of rVV in organs of IFN knockout mice.
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reported, indicating that IL-15 has additional antiviral functions (Gill
et al., 2005). Clearly the mechanisms for IL-15-mediated antiviral
effects are not fully understood and warrant further investigation. An
early landmark study used rVV expressing human IL-15 to demon-
strate potent antiviral function for IL-15 in vivo (Perera et al., 2001).
Here we have extended these ﬁndings, ﬁrst by identifying key cells
and cytokines involved in the antiviral activity of IL-15, and second, by
using an rVV expressing mouse (rather than human) IL-15 to more
accurately model the function of this cytokine in vivo. In particular, we
demonstrate that the antiviral effect of IL-15 during a generalized
vaccinia virus infection in vivo is dependent on the presence of IFNs.
To the best of our knowledge this is the ﬁrst study to demonstrate a
requirement for IFNs in IL-15-mediated antiviral activity in vivo.Table 2
Mortality of knockout and wild-type mice following infection with VV-IL-15 or VV-X.
Mouse strains VV-IL-15 VV-X
% mortality (MTD)* % mortality (MTD)*
WT (129/SvEv) NM 62.5%
IFN-α,β,γ R−/− (129/SvEv) 100% (4.8±0.4*) 100% (3.9±0.3*)
IFN-α,β R−/− (129/SvEv) NM 100% (13.8±0.9*)
IFN-γ R−/− (129/SvEv) NM 100% (25±1.3*)
WT (C57BL/6) NM 50%
IFN-γ (C57BL/6) NM 100% (26.6±1.1*)
Groups of 8 mice were infected intravenously with 107 pfu of VV and observed for
50 days.
NM: no mortality observed.
⁎The mean time to death (days)±SEM is given for groups with 100% mortality.Similar to the study by Perera et al. (2001), we found that the
antiviral activity of IL-15 was expressed rapidly following infection of
mice with VV-IL-15. Taken together with the very early expression of
IL-15 during VV infection (Fig. 1), these data indicate that IL-15 could
play an important role in the early immune response to virus
infection. This observation is consistent with other studies demon-
strating the early activity of IL-15 in resolving infections. For example,
infecting mice with intracellular bacteria such as Mycobacteria
(Doherty et al., 1996), Listeria (Hirose et al., 1998) and HSV-2 (GillVirus and mouse strains Spleens
(Log10 virus titers±SEM)
Ovaries
(Log10 virus titers±SEM)
VV-X
WT (129/SvEv) 3.0±0.1 6.6±0.2
IFN-γ R−/− (129/SvEv) 4.5±0.13 6.3±0.1
IFN-α,β R−/− (129/SvEv) 4.3±0.5 7.1±0.2
IFN-α,β,γ R−/− (129/SvEv) 4.8±0.4 7.7±0.1
VV-IL-15
WT (129/SvEv) No virus detected 4.8±0.11
IFN-γ R−/− (129/SvEv) 3.1±0.06a 6.7±0.08
IFN-α,β R−/− (129/SvEv) 3.5±0.2a 6.5±0.1
IFN-α,β,γ R−/− (129/SvEv) 4.7±0.15b 7.0±0.11
Groups of 4 mice were infected intravenously with 107 pfu of VV and spleens and
ovaries were collected 3 days post infection to determine viral titers. The limit of
detection of the assay is 2 log10 pfu/ml.
a pb0.05, compared to IFN-γ R−/− or IFN-α/β R−/− mice infected with VV-X.
b pb0.05, compared to IFN-γ R−/− or IFN-α/β R−/− mice infected with VV-IL-15.
Table 4
Effect of treatment with antibodies to IFN-γ or IFN-α/β or both on rVV replication in
C57BL/6 mice.
Virus and treatment Spleens
(Log10 virus titers±SEM)
Ovaries
(Log10 virus titers±SEM)
VV-X
+GL113 2.7±0.2 5.9±0.4
+anti-IFN-γ 3.9±0.3 6.1±0.2
+anti-IFN-α/β 3.6±0.4 6.5±0.3
+anti-IFN-γ+anti-IFN-α/β 4.3±0.4 7.2±0.4
VV-IL-15
+GL113 No virus detected 4.2±0.1
+anti-IFN-γ 2.8±0.1a 5.8±0.5
+anti-IFN-α/β 2.9±0.3a 6.0±0.4
+anti-IFN-γ+anti-IFN-α/β 3.9±0.5b 6.9±0.2
Groups of 3 C57BL/6 mice were treated with antibodies to IFN-γ, IFN-α/β, IFN-γ+IFN-
α/β or the irrelevant control GL113 and infected intravenously with 107 pfu virus. Mice
were killed 3 days post infection and virus titers in the spleen and ovaries determined.
a pb0.05, compared to VV-X infected mice depleted of either IFN-γ or IFN-α/β.
b pb0.05, compared to VV-IL-15 infected mice depleted of either IFN-γ or IFN-α/β.
234 Y.Y. Foong et al. / Virology 393 (2009) 228–237et al., 2005; Tsunobuchi et al., 2000) induced the early production of
IL-15 that was necessary for protection against these pathogens.
NK cells are key contributors to the early antiviral response
through their cytolytic activity and production of soluble mediators
(Biron and Brossay, 2001). Previous studies have shown a strong
association between IL-15 and NK cell activity (Carson et al., 1994;
Perera et al., 2001; Puzanov et al., 1996), conﬁrmed by our ﬁndings of
enhanced NK activity in mice infected with VV-IL-15. The increased
NK activity represents a major antiviral mechanism for IL-15, since
depletion of NK cells markedly reversed the attenuation of VV-IL-15.
However, VV-IL-15 titers in NK depleted mice were still lower than in
mice infected with VV-X, especially in the spleen, suggesting that
additional early immune components may contribute to the antiviral
effects of IL-15.
IL-15 can stimulate production of IFNs from a range of immune
effector cells (Carson et al., 1999; Jinushi et al., 2003; Liu et al., 2004),
and we hypothesized that IFNs could mediate the antiviral activity ofFig. 8. VV-IL-15 mediated antiviral activity. IL-15 expressed by rVV can directly increase t
activation of the transcription factors IRF-1, NF-κB and IFNs in natural killer (NK) cells, macr
and antigen presenting cells.IL-15. Infection with VV-IL-15 resulted in elevated expression of IFNs
and the IFN-related transcription factors NF-κB and IRF-1, and
represents a highly plausible mechanism for the antiviral activity of
rVV encoded IL-15. The majority of IL-15-mediated IFN production
could be attributed to NK cells, since depletion of NK cells resulted in
complete reduction in IFN-γ mRNA expression, and substantial
reduction in IFN-β mRNA expression. Based on these results we
conclude that non-NK cells also contribute to the elevated IFN
production following infection with VV-IL-15. IL-15-mediated pro-
duction of type I IFNs may represent a key step in the rapid
ampliﬁcation of NK cell function since type I IFNs can themselves
enhance NK cell activation during VV infection (Martinez et al., 2008).
Using IFN-deﬁcient mice, and neutralizing antibodies, we demon-
strated that the antiviral activity of virus-encoded IL-15 required the
activity of both IFN-α/β and IFN-γ. Mice lacking receptors for IFN-α/β
or IFN-γ were highly susceptible to infection with VV-X, but were
partially resistant to infection with VV-IL-15. In contrast, mice lacking
receptors for both IFN-α/β and IFN-γ were highly, and equally,
susceptible to VV-X and VV-IL-15. From these results, we conclude
that the antiviral activity of virus-encoded IL-15 involves both IFN-α/β
and IFN-γ, and that the activity of the IFNs accounts fully for the
antiviral activity of IL-15. Although previous studies have observed
elevated IFN-β production associated with antiviral activity of IL-15
(Gill et al., 2005), this is the ﬁrst demonstration that IFNs are critical for
IL-15 mediated antiviral activity in vivo. Our study also shows that NK
cells are the major source of IL-15-induced IFN production, but that
additional cells, as yet unidentiﬁed, also contribute to IFN-β production.
In summary, IL-15 expressed by rVV infection contributed to virus
clearance via direct and indirect pathwayswhich included: i) enhanced
NK cytolytic activity, ii) increased secretion of IFNs (IFN-γ, IFN-β) and
downstream IFN-inducible proteins by NK cells and other cells, and iii)
increased IRF-1 activity, a potent regulator of IFNs and IL-15
expressions (Fig. 8). In conclusion, the use of viral vectors encoding
IL-15 in the designof vaccines could providenew therapeutic strategies
aimed at boosting the innate immune response. This was recently
demonstrated in mice, with the integration of human IL-15 into thehe cytolytic activity of NK cells. In addition, the over-expression of IL-15 triggers the
ophages and non-immune cells. These factors mediate antiviral effects by activating NK
235Y.Y. Foong et al. / Virology 393 (2009) 228–237modiﬁed vaccinia virus Ankara (MVA-IL-15) that showed greater
immunogenicity and efﬁcacy than the currently licensed smallpox
vaccine (Dryvax) (Perera et al., 2007).
Materials and methods
Mice
Speciﬁc-pathogen-free athymic Swiss outbred nude and C57BL/6
wild-type (WT) mice were used at 6–12 weeks of age. Mice lacking
functional type I IFN receptor [IFN-α/β R GKO] and both type I and
type II IFN receptors [IFN-α/β, γ R GKO] (van den Broek et al., 1995)
on the 129/SvEv background were used at 6–12 weeks of age. Wild-
type 29/SvEv mice were used as controls for the GKO mice. Mice
deﬁcient in the IFN-γ gene (Dalton et al., 1993) on the C57BL/6
background were used at 6–12 weeks of age. All IFN receptor gene-
knockout mice were bred on the 129/SvEv mouse strain, with the
exception of IFN-γ−/− mice which were bred on the C57BL/6 mouse
strain. All mice were obtained from the Animal Breeding Establish-
ment, John Curtin School of Medical Research and treated according to
the Australian National University Animal Welfare guidelines.
Viruses
The neurovirulent VV strain, Western-Reserve (VV-WR), was
propagated in CV-1 African green monkey kidney cells and used
after puriﬁcation on a sucrose density gradient, as previously
described (Esposito et al., 1978). Mice were injected intravenously
(i.v.) on day 0 with 106 plaque-forming units (pfu) of the virus. Wild-
type vaccinia virus VV-WR was used to generate all rVV used in this
study following previously described methods (Coupar et al., 1988;
Ramshaw et al., 1987). In experiments where mice were injected with
recombinant vaccinia virus (rVV) expressing murine IL-15 (VV-IL-15)
or murine IL-2 (VV-IL-2), VV-X (Coupar et al., 1988) was used as the
control virus. Mice were infected intravenously (i.v) or intraperitone-
ally (i.p) with rVVs. Prior to infection, virus stocks were diluted in
phosphate-buffered saline (PBS) to the required titer and sonicated
three times at 50 W for 10 s.
Cell lines
143B, YAC-1 and CTLL-2 cell lines were obtained from the
American Type Culture Collection (ATCC). All cell lines were
maintained in DMEM (Gibco BRL) supplemented with 5% heat-
inactivated fetal calf serum (FCS) (CSL, Australia), 1 mM L-glutamine
(Gibco BRL), 10 mM HEPES (Gibco BRL) and antibiotics. Human
osteosarcoma 143B cells were used for viral propagation of VV-X, VV-
IL-15 and VV-IL-2 and for viral titrations. CTLL-2 cells were used in a
proliferation assay tomeasure IL-15 bioactivity. YAC-1 cells were used
as target cells for NK cell cytotoxicity assays.
RNA extraction and RT-PCR analysis of cytokines
Total RNA was isolated from the spleens of rVV-infected mice by
standard methods using TRIzol (Gibco BRL). Reverse-transcriptase
PCR (RT-PCR) was performed, as described previously (Mahalingam
et al., 2001a; Mahalingam and Lidbury, 2002). Primer sequences for
HPRT, IFN-β, IFN-γ and IRF-1 have been described previously (Lidbury
and Mahalingam, 2000; Mahalingam et al., 1999, 2001b). Primer
sequences for IL-15 and IL-2 are as follows: IL-15 sense (5′ GAACAGT-
GACGGATCCCCC 3′) and antisense (5′ CGGTATCGATAAGCTTGATA 3′);
IL-2 sense (5′ GAGTCAAATCCAGAACATGCC 3′) and antisense (5′
TCCACTTCAAGCTCTACAG3′). The cyclenumbers used for ampliﬁcation
of each gene product is as follows: IFN-γ and IRF-1, 25 cycles; IFN-β and
IL-15, 28 cycles; and HPRT, 23 cycles. After the appropriate number of
PCR cycles, the ampliﬁed DNA was analyzed by gel electrophoresis.ELISA for mouse IL-15
IL-15 protein was detected using the method described by Gill
et al. (2005). Brieﬂy, Maxisorp 96-well ELISA plates (Invitrogen)
were coated with 100 μl of rabbit anti-mouse IL-15 (RDI) (2 g/ml)
and incubated overnight at 4 °C. Plates were washed with PBS-Tween
20, blocked with 2% bovine serum albumin (BSA) at room
temperature for 2 h and diluted samples (in 0.1% BSA) were
incubated overnight at 4 °C. Plates were incubated with 100 μl of
goat anti-mouse IL-15 (1 g/ml) (R&D Systems) for 1 h in the dark at
room temperature followed by 100 μl of biotin-labeled donkey anti-
goat antibody (RDI) (0.1 g/ml) at room temperature for 1 h. Plates
were developed by the addition of Extravidin peroxidase conjugate
(Sigma) for 45 min at room temperature and TMB microwell
peroxidase (KPC) for 30 min at room temperature. Reactions were
stopped by the addition of 100 μl of 1 M H2SO4, and plates read with
an ELISA plate reader (BioRad) at 405 nm.
ELISA for mouse IFN-γ
The concentration of IFN-γ in mouse tissue samples was
determined by ELISA (R&D Systems) as speciﬁed by themanufacturer.
Construction of recombinant vaccinia virus
Recombinant VV encoding murine IL-15 was made from the wild-
type VV-WR virus using established procedures (Coupar et al., 1988;
Mahalingam et al., 1999). The generation of recombinant viruses were
based on thymidine kinase (TK) recombination, making recombinant
control virus VV-X less virulent than VV-WR. Full-length murine IL-15
cDNA (Immunex Corp.) was excised from pBluescriptSK− using Sal1
and BamH1 restriction enzymes. The 545 base pair (bp) insert was gel
puriﬁed and cloned into the BamH1 and Sal1 sites of the digested
vector pPS7.5A (Coupar et al., 1988). Expression of mIL-15 is under
the control of the early/late VV 7.5 kDa promoter P7.5, and the
resulting plasmid, designated pPS7.5A-IL-15, was used in a marker
rescue with VV-PR8 (HSV thymidine kinase negative virus, TK- virus)
(Mahalingam et al., 1999). In vitro homologous recombination with
VV-PR8 and pPS7.5A-IL-15 using marker rescue of the TK gene and
methotrexate selection resulted in VV-IL-15 which encoded the IL-15
cDNA. Following three rounds of plaque puriﬁcation, the absence of
wild-type VV-WR virus and the presence of IL-15 was conﬁrmed by
PCR analysis, as previously described (Heine and Boyle, 1993).
Protein expression by recombinant IL-15 virus
Immunoﬂuorescence assay
The expression of foreign protein by rVV was conﬁrmed by
immunoﬂuorescence cell staining. Cell monolayers (143B cells) were
grown on glass coverslips and infected with rVV at a multiplicity of
infection (moi) of 0.1 for 18 h. Cells were ﬁxed in methanol at−20 °C
for 20 min, washed twice with PBS and permeabilised with 0.2%
Triton-X100. Polyclonal anti-murine IL-15 antibody (R&D Systems)
was added to each coverslip for a minimum of 20 min at room
temperature before washing three times in PBS. FITC-conjugated anti-
goat Ig (for IL-15 staining) antibody was added (1/20 dilution) for a
minimum of 20 min. The ﬁxed cells were washed and antibodies were
diluted using PBSFT buffer (2% FCS, 0.2% Triton-X100 in PBS). After
washing three timeswith PBS, the glass coverslips were quickly rinsed
in water to remove salt crystals andmounted in glycerol/PBS (1:1) on
glass slides. Immunoﬂuorescence of stained cells was visualized using
a BioRad Radiance 2000 Confocal Laser Scanning Microscope (CLSM)
system using a Nikon Eclipse TE300 invertedmicroscope and a 60× oil
immersion lens. Where required, transmission mode images were
overlayed onto ﬂuorescent images to enable subcellular localization of
ﬂuorescent signals to be determined.
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IL-15 protein expression by rVV was determined using a CTLL-2
bioassay. Conﬂuent monolayers of 143B cells were infected with
VV-IL-15 and the parent virus VV-PR8 at a moi of 1 for 48 h.
Supernatant was collected, centrifuged at 2000 rpm for 10 min and
virus in the supernatant was removed by ﬁltering the supernatant
twice through 0.1 μm ﬁlters (Millipore). The cell ﬁltrate was
concentrated using Centricon-10 (Amicon) concentrators for 60 min
in a SS34 Sorvall rotor at 5000 g before storage at −20 °C.
Concentrated protein was titrated in 96-well plates before seeding
with 104 log-phase CTLL-2 cells per well. Cells were incubated for
48 h at 37 °C with 5% CO2 before the addition of CellTiter96®
Aqueous One Solution Reagent (Promega). Cell proliferation was
assessed by reading the absorbance at 490 nm 4 h after the addition
of the color reagent.
Nuclear extraction
Spleen tissues were collected from groups of WT C57BL/6 mice
3 days after infection with VV-X or VV-IL-15 and cell suspensions
prepared as previously described (Mahalingam et al., 2001a). Nuclear
extracts were prepared according to the method described previously
(Dignam et al., 1983).
Electrophoretic mobility shift assay (EMSA)
The sequences foroligonucleotidesused and theEMSAprotocol have
been described previously (Mahalingam and Lidbury, 2002). Double-
stranded oligonucleotides were labeled with 32P-deoxynucleotide
(Amersham) using Klenow polymerase (Roche). The reaction mixture
contained nuclear extract (10 μg), 5 μg of poly(dI-dC), 1 mM
dithiotreitol and 1 μl of 32P-labeled double-stranded oligonucleotides
(0.1 μg/μl) dissolved in the binding buffer (pH 7.9, 20 mM Tris–HCl,
30 mM NaCl, 5 μM EGTA, 50% glycerol) supplemented with 0.2 μg/ml
BSA. Following incubation, electrophoresis was performed in TBE buffer
(89mMTris base, 89mMboric acid, 2mMEDTA, pH8)at175V. The gels
were dried and analyzed by autoradiography.
Cytotoxicity assays
The standard 51Cr-release assay for NK cell cytotoxicity was
performed in triplicate for each effector to target ratio, as described
elsewhere (Karupiah et al., 1990).
Determination of virus titers in organs
Ovaries and spleens were removed aseptically from groups of
virus-infected mice and stored at −70 °C. Organs were thawed and
homogenized in 1 ml PBS. A 100 μl aliquot of the homogenate was
incubated with 100 μl trypsin (1 mg/ml) at 37 °C for 30 min, after
which DMEMmedia with 5% FCS was added to a ﬁnal volume of 1 ml.
Ten-fold serial dilutions were carried out in saline with 0.5% gelatin
and 100 μl of each dilution used to infect conﬂuent 143B cell
monolayers grown in six-well plates (Linbro, Flow Laboratories,) at
37 °C with 5% CO2. After 48 h, cells were stained with 0.1% crystal
violet in 20% ethanol and viral plaques counted. The limit of detection
for this assay was 2 log10 pfu/ml.
Histology
Ovaries were collected frommice and ﬁxed in 10% neutral buffered
formalin for at least 24 h before embedding in parafﬁn wax. Fixed
tissues were sectioned into 5 μm slices, stained with haematoxylin
and eosin (H & E) and mounted onto glass slides. Analysis of stained
tissue sections was performed using a Nikon CoolPix 990 Zeiss
Axiophot photomicroscope.Depletion of NK cells in vivo
A mouse monoclonal antibody, PK136, was used to deplete
C57BL/6 mice of NK (NK1.1+) cells. PK136 is a highly speciﬁc, anti-
NK1.1+ antibody (Koo et al., 1986), obtained from ascites as a gift
from Dr. Guna Karupiah (Australian National University). NK cells
were depleted in the mice by i.p. injection with 1 mg of PK136
diluted in PBS on days −1 and 1. Mice were infected on day 0 with
107 pfu virus and on day 3 the ovaries and spleens were harvested to
determine viral titers. Single cell suspensions from spleens were
prepared to verify NK depletion by ﬂuorescent activated cell sorter
(FACS) analysis.
Neutralization of IFN-γ and IFN-α/β in vivo
Neutralization of IFN-γ in vivo was performed using a monoclonal
antibody (MAb) (clone XMG-6; rat IgG1). A MAb to β-galactosidase
(clone GL113; rat IgG1) was used as an isotype control. Puriﬁed rabbit
polyclonal antibody to murine IFN-α/β (Lee Biomolecular Research
Laboratories) was used to neutralize IFN-α/β. Mice were given 1 mg
each of MAb to IFN-γ or 300 U each of anti-IFN-α/β or a combination
of the two antibodies i.p. on days−1 and 1. Control mice were given
1 mg of anti-β-galactosidase MAb. Mice were infected with 107 pfu
virus on day 0 and killed on day 3.
Statistical analysis
Data is expressed as mean±standard error of the mean (SEM).
Differences between experimental groups were analyzed using either
Students t-test (InStat 2.01 software for Macintosh) or one-way
analysis of variance (ANOVA) test using GraphPad Prism4 software.
Values of pb0.05 were considered signiﬁcant.
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